Immunovant shares fall 6% after lupus study misses primary endpoint
AI Summary- Immunovant disclosed that its IMVT-1402 lupus study missed its primary endpoint and discontinued the program.
- Shares fell approximately 6% on September 23, 2026, reaching a more-than-three-month low.
- SueWallSt announced an investigation into potential securities law violations involving Immunovant investors' losses.